Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(1.78) per share which missed the analyst consensus estimate of $(0.65) by 173.85 percent. This is a 72.19 percent increase over losses of $(6.40) per share from the same period last year.